ערך בספרים למניה: uniQure Corp (QURE)

This chart of the market valuation of uniQure N.V. (QURE) demonstrates the asset's dynamics, where the key indicator is 4.66. uniQure N.V. (QURE) leads in the treatment of hemophilia due to its own manufacturing plants and established gene transport systems. R&D monetization is driven by high-cost single-dose injections and patent protection. Meanwhile, the business strictly adheres to bio-waste disposal regulations and implements energy-efficient technologies.

Book value per share represents the portion of equity attributable to a single security. For uniQure N.V. (QURE), this metric reflects a financial safety buffer given the company's reliance on a single commercial drug. The trend in book value per share demonstrates the company's ability to maintain assets amidst market competition. This metric allows for an assessment of the business's intrinsic value, excluding market speculation. It serves as a critical indicator of solvency and resilience to operational risks.